Celgene Joins Forces with Leading Patient Advocacy Organizations on
World Pancreatic Cancer Day - 13 November 2014 - to Raise Awareness
About this Major Cancer Killer
SUMMIT, N.J.--(BUSINESS WIRE)--
While it may not be surprising that breast and lung cancers are top of
mind when people hear the word "cancer," 60% of respondents to a recent
six-country survey about cancer awareness know almost nothing about
pancreatic cancer, a leading cancer killer. Pancreatic cancer is the
fourth leading cause of cancer-related deaths in the US and is projected
to be the second highest cause of death from cancer in the US by 2020.
The overall five-year survival rate in the US and Europe is less than
7%; this rate has been low for many years and is among the lowest for
common cancers in the US and across most countries in Europe.
Today, in observance of the first ever World Pancreatic Cancer Day,
Celgene joins with the international pancreatic cancer patient advocacy
community to raise the level of education and awareness about this
cancer and the need for change. In support of this effort, Celgene is
releasing results of a Global Pancreatic Cancer Awareness Omnibus
Survey of more than 7,000 adults in the United States and Europe.
The survey was sponsored by Celgene and conducted by Ipsos in early 2014
and was designed to assess the level of awareness and knowledge about
pancreatic cancer, the degree of interest in learning more about this
deadly cancer, and the level of support for expanded research efforts.
The survey affirmed that the majority (84%) of adults in these countries
view cancer as a serious public health problem, topping a list of
diseases that also included heart disease, Alzheimer's disease, obesity,
diabetes and mental illness. When all respondents were asked, unaided,
which specific cancers are top of mind, just 2% of those surveyed
mentioned pancreatic cancer as the first type of cancer that came to
mind, while 37% mentioned breast cancer and 20% mentioned lung cancer.
This picture changed dramatically, however, when all respondents were
made aware of the poor survival associated with pancreatic cancer, with
more than 70% indicating they would be extremely/very supportive of a
public awareness campaign supporting more public education about
pancreatic cancer and about half of all respondents indicating they
would take action to support public awareness.
"The Global Pancreatic Cancer Awareness Omnibus survey underscores the
ongoing need to raise awareness of pancreatic cancer and to support
efforts for additional resources for research," said Julie Fleshman,
president and chief executive officer, Pancreatic Cancer Action Network.
"It's clear that when people understand the seriousness of pancreatic
cancer they want to take action. The first-ever World Pancreatic Cancer
Day set by the international pancreatic cancer advocacy community offers
the perfect opportunity to start turning this aspiration into a global
effort to raise awareness about pancreatic cancer and make a difference
in the lives of those diagnosed with this cancer."
As part of World Pancreatic Cancer Day, the international pancreatic
cancer patient advocacy community, with the support of Celgene, is
embarking on several initiatives to jumpstart efforts to call attention
to pancreatic cancer. Anyone interested in participating in the first
ever World Pancreatic Cancer Day can visit www.worldpancreaticcancerday.org
for more information on activities happening around the world and use
#WPCD2014, #WorldPancreaticCancerDay in social media posts.
"Celgene has long been committed to addressing the needs of pancreatic
cancer patients and is proud to be partnering with pancreatic cancer
organizations around the world to raise awareness about the disease and
the progress made thus far against this deadly cancer," said Markus
Renschler, MD, Senior Vice President and Global Head, Hematology &
Oncology Medical Affairs for Celgene. "Putting a dent in the rather grim
pancreatic cancer statistics will be challenging, but with appropriate
treatment and the more than 170 global clinical trials evaluating
investigational treatments in approximately 35,000 patients we believe
outcomes will be improved for patients with this deadly disease."
Additional survey findings showed:
In both the US and Europe, pancreatic cancer is the cancer type
respondents are least knowledgeable about among seven common cancers,
with 49% in the US and 64% in Europe saying they know almost nothing
about it, with Spain and France being the least knowledgeable (26% and
35% know a lot or a fair amount).
In the US and Europe, three in four respondents feel it is very
important that the public be aware of pancreatic cancer; this is on
par with feelings about awareness of other cancers (breast, lung,
melanoma/skin, colon, prostate, and ovarian).
61% of respondents in all countries surveyed rank supporting ways to
increase screening and earlier diagnosis of pancreatic cancer as being
among the most important goals in terms of raising awareness about
pancreatic cancer, followed by a call for more research to prevent
this type of cancer (53%). Both France and the UK rated the goal to
increase screening and earlier diagnosis higher than other countries
(69% and 70%, respectively).
Women (42%) are more likely than men (33%) to rank supporting ways to
increase screening and earlier diagnosis as a top goal; this was true
for every country surveyed but Spain. Men are more likely to consider
more research into its prevention (28% vs. 25%), fundraising for
improved treatments (14% vs. 12%), and raising awareness about lack of
progress in treatments (13% vs. 11%) as important goals when it comes
to raising public awareness about pancreatic cancer.
Progress Against Cancer
The majority of adults in the EU (88%) and US (89%) strongly/somewhat
agree that while progress has been made against cancer, more should
have been done over the past 20 years.
Respondents in the US and Europe hold nearly identical views regarding
improvements in treating cancer. There is near universal agreement
that there should be a greater focus on improving treatments and
finding cures, with two thirds strongly agreeing.
Knowledge About and Experience with Cancer
Breast cancer is the most-cited type of cancer followed by lung cancer
in every country, with more than one-third of all respondents
mentioning breast cancer as the cancer type that first
comes to mind when they hear the word "cancer."
Top-of-mind mentions of breast cancer are particularly high in the
UK (46%), France (45%), and Spain (40%) relative to other types of
cancer, but less so in Germany (29%), where it is mentioned only
slightly more frequently than lung cancer, and in Italy (29%).
Compared to those surveyed in Europe, respondents in the US are more
likely to consider themselves knowledgeable regarding all of
the types of cancer presented (breast, lung, melanoma/skin, colon,
prostate, ovarian, pancreatic). Knowledge levels tend to be highest
for breast and lung cancers - which also are the cancers that are most
For example, 78% in the US and 66% in Europe know a lot/at least a
fair amount about breast cancer. For lung cancer, a lot/at least a
fair amount is known by 71% in the US and 59% in Europe.
Conversely, 49% in the US and 64% in Europe surveyed said they
know almost nothing about pancreatic cancer.
Overall, 7 in 10 respondents globally know someone who has had one of
the cancer types mentioned, including 11% who know someone who has had
pancreatic cancer. Respondents in France are least likely to say that
a loved one has had any of the cancers that were listed, including
Involvement in Public Awareness
When it comes to who should be involved in increasing public awareness
about cancer, respondents in all countries believe that medical
researchers/scientists should take the lead in this effort (70%),
followed closely by medical societies (60%) and non-profit cancer
The majority of respondents in the US - more so than in Europe - are
more likely to believe that almost all groups (medical researchers,
non-profit cancer organizations, medical societies, patient advocacy
groups, and companies making cancer treatments) except government
should play a leading or significant role. In contrast, European
respondents are more likely to say that government should play a
Half of all respondents globally would take action to support public
awareness of pancreatic cancer, including majorities in the US, Italy,
About Pancreatic Cancer
Currently, there are no early screening or detection methods, and early
symptoms can be similar to those of many other diseases. This means that
pancreatic cancer is not usually diagnosed until it is at an advanced
stage. For this reason, most patients have a poor prognosis, with more
than one-half of patients diagnosed after their cancer has metastasized
(spread to other organs).
While the incidence and death rates for cancer as a whole are declining,
those for pancreatic cancer are on the rise. More than 100,000 people in
Europe currently have a diagnosis of pancreatic cancer. In
2014, it is estimated more than 46,000 people in the United States will
be diagnosed with pancreatic cancer, and nearly 40,000 people will die
of the disease. Currently, only about 26 percent of patients
with pancreatic cancer survive for one year following diagnosis. For
patients who are not diagnosed until after the cancer has already spread
(metastasized), the outlook is even bleaker— the average survival time
is only three months. Unfortunately, this is the case for more than half
of patients with pancreatic cancer.
About the Survey
The Global Pancreatic Cancer Awareness Omnibus Survey
assessed perceptions about the seriousness of cancer relative to other
diseases and focused, in particular, on level of awareness and
understanding about pancreatic cancer. The survey was sponsored by
Celgene and conducted by Ipsos' online omnibus among 2014 adults age 18+
in the United States between January 31 and February 4, 2014 and roughly
1000 adults between February 4-18, 2014, age 16+ in each of the
following European countries: France, Germany, Italy, Spain, and the UK.
Weighting was employed to balance demographics and to ensure sample
composition reflects that of each country's population of adults
according to census data and to provide results intended to approximate
the sample universe.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in the
discovery, development and commercialization of novel therapies for the
treatment of cancer and inflammatory diseases through gene and protein
regulation. For more information please visit www.celgene.com.
Follow us on Twitter @Celgene
Source: Celgene Corporation
News Provided by Acquire Media